Join
Live feed
·
PRReleasevia Quantisnow
Provention Bio Inc. logo

TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D

ByQuantisnow·Wall Street's wire, on your screen.
PRVB· Provention Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRVB (Provention Bio Inc.) and more on Quantisnow.